Epigenomics AG

EANS-News: Epigenomics AG
Predictive Biosciences launches prostate cancer test based on Epigenomics' DNA methylation marker

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.

Company Information/New Products/molecular diagnostics

Berlin, Germany, Seattle, WA, and Lexington, MA, U.S.A. (euro adhoc) -
Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer
molecular diagnostics company, and Predictive Biosciences, an innovative
developer of molecular diagnostic tests, today announced that Predictive
Biosciences of Lexington, MA, has made commercially available a novel
tissue-based test for prostate cancer biopsy confirmation utilizing Epigenomics'
proprietary DNA methylation marker GSTP1.

Pierre Cassigneul, Chief Executive Officer of Predictive Biosciences, stated:
"We are excited to build upon our existing CertNDx? commercial franchise in
bladder cancer, with the first of several novel tests we plan to commercialize
over the next few years which will address the significant unmet diagnostic
clinical needs in prostate cancer".

Additionally, Noel Doheny, Chief Executive Officer of Epigenomics' US
subsidiary, commented: "We are pleased that Predictive Biosciences has
successfully moved forward to introduce their assay based on Epigenomics'
intellectual property into the market. This further demonstrates the growing
importance of DNA methylation based tests in cancer diagnostics".

- Ends -

Contact Epigenomics AG

Antje Zeise
Manager IR | PR 
Epigenomics AG 
Tel +49 (0) 30 24345 368 

About Predictive Biosciences
Predictive Biosciences develops novel molecular diagnostic cancer assays and
provides molecular pathology services for urology-based practices. Leveraging a
portfolio of patented biomarkers and clinical approaches, the company has built
a unique portfolio of assays for cancer management, first targeted at bladder
and prostate cancer. For additional information, please visit

About Epigenomics
Epigenomics (www.epigenomics.com) is a molecular diagnostics company developing
and commercializing a pipeline of proprietary products for cancer. The Company's
products enable doctors to diagnose cancer earlier and more accurately, leading
to improved outcomes for patients. Epigenomics' lead product, Epi proColon®, is
a blood-based test for the early detection of colorectal cancer, which is
currently marketed in Europe and is in development for the U.S.A. The Company's
technology and products have been validated through multiple partnerships with
leading global diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest
Diagnostics. Epigenomics is an international company with operations in Europe
and the U.S.A.

Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements involve
certain known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or achievements of
Epigenomics AG to be materially different from any future results, performance
or achievements expressed or implied by such forward-looking statements.
Epigenomics AG is providing this communication as of this date and does not
undertake to update any forward-looking statements contained herein as a result
of new information, future events or otherwise. 

The information contained in this communication does not constitute nor imply an
offer to sell or transfer any product, and no product based on this technology
is currently available for sale by Epigenomics in the United States or Canada.
The analytical and clinical performance characteristics of any Epigenomics
product based on this technology which may be sold at some future time in the
U.S. have not been established.

Further inquiry note:
Antje Zeise | CIRO 
Manager IR/PR 
Epigenomics AG
Tel: +49 30 24345 386

end of announcement                               euro adhoc 

company:     Epigenomics AG
             Kleine Präsidentenstraße 1
             D-10178 Berlin
phone:       +49 30 24345-0
FAX:         +49 30 24345-555
mail:     ir@epigenomics.com
WWW:      http://www.epigenomics.com
sector:      Biotechnology
ISIN:        DE000A1K0516
indexes:     Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
             regulated dealing/prime standard: Frankfurt 
language:   English

Weitere Meldungen: Epigenomics AG

Das könnte Sie auch interessieren: